BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA

* Abbvie receives Orphan Drug Designation for

investigational IL-23 inhibitor Risankizumab from the U.S. Food

and Drug Administration for the treatment of pediatric patients

with Crohn's Disease

Source text for Eikon:

Further company coverage:

Read more